- Home
- MIRM vs INTA Comparison
MIRM vs INTA Comparison
Compare MIRM & INTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- INTA
- Stock Information
- Founded
- MIRM 2018
- INTA 2000
- Country
- MIRM United States
- INTA United States
- Employees
- MIRM 349
- INTA N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- INTA Computer Software: Prepackaged Software
- Sector
- MIRM Health Care
- INTA Technology
- Exchange
- MIRM Nasdaq
- INTA Nasdaq
- Market Cap
- MIRM 3.7B
- INTA 3.3B
- IPO Year
- MIRM 2019
- INTA 2021
- Fundamental
- Price
- MIRM $72.85
- INTA $39.42
- Analyst Decision
- MIRM Strong Buy
- INTA Buy
- Analyst Count
- MIRM 11
- INTA 9
- Target Price
- MIRM $76.09
- INTA $62.50
- AVG Volume (30 Days)
- MIRM 712.9K
- INTA 660.8K
- Earning Date
- MIRM 11-11-2025
- INTA 11-03-2025
- Dividend Yield
- MIRM N/A
- INTA N/A
- EPS Growth
- MIRM N/A
- INTA N/A
- EPS
- MIRM N/A
- INTA N/A
- Revenue
- MIRM $429,161,000.00
- INTA $504,120,000.00
- Revenue This Year
- MIRM $53.14
- INTA $15.18
- Revenue Next Year
- MIRM $19.83
- INTA $13.51
- P/E Ratio
- MIRM N/A
- INTA N/A
- Revenue Growth
- MIRM 62.33
- INTA 17.09
- 52 Week Low
- MIRM $36.88
- INTA $35.51
- 52 Week High
- MIRM $78.10
- INTA $77.74
- Technical
- Relative Strength Index (RSI)
- MIRM 56.46
- INTA 32.65
- Support Level
- MIRM $70.49
- INTA $38.38
- Resistance Level
- MIRM $74.96
- INTA $40.42
- Average True Range (ATR)
- MIRM 1.82
- INTA 1.21
- MACD
- MIRM -0.72
- INTA -0.46
- Stochastic Oscillator
- MIRM 51.03
- INTA 10.03
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About INTA Intapp Inc.
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital,g, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.